This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Diagnosis and Treatment of ILD with a Progressive Lung Disease Phenotype: Clinical Implications of Emerging Data

Diagnosis and Treatment of ILD with a Progressive Lung Disease Phenotype: Clinical Implications of Emerging Data

Format

Slide Lecture Series

Time to Complete

1 hour

Released

November 16, 2018

Expires

November 15, 2019
Add to Queue


Maximum Credits

1.00 / AMA PRA Category 1 CreditTM

Accredited Provider



Provided by National Jewish Health

Commercial Supporter

Supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Program Description

The arrival of new therapeutic options for Idiopathic Pulmonary Fibrosis (IPF) has stimulated vigorous interest in the Interstitial Lung Diseases (ILDs) that are associated with rapid progression. In order for patients with ILD to benefit fully from new developments, more physicians need to be able to competently identify, monitor, and treat patients who present with or are at risk for an ILD Progressive Lung Disease Phenotype (PLDP). In this activity, three patient cases are highlighted to demonstrate stable, moderate, and rapid progressive ILD and include corresponding HRCT images and HRCT reconstructions with 3D animations. In addition, a downloadable infographic clinical reference aid is included to reinforce key learning points related to best practices for classifying ILD subtypes and phenotypes.

Diagnosing ILD Infographic

To download the Diagnosing ILD Infographic (PDF), please click here. This is also available for download in the content section of the activity.

Intended Audience

This activity is intended for Pulmonologists, Radiologists, Pathologists, Primary Care Physicians, Physician Assistants and Advanced Practice Nurses engaged in the care of patients with ILD.

Educational Objectives

After completing this activity, participants should be better able to:

  • Describe best practices for classifying ILD subtypes and phenotypes.
  • Define ILD with a progressive phenotype in new patients and as the disease changes over time.
  • Discuss strategies for initial treatment and management protocols for patients with a progressive ILD phenotype.

Conflicts of Interest Disclosure Policy

National Jewish Health requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved. National Jewish Health is committed to providing its learners with high quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty

Joshua Solomon, MD, FCCP (Program Chair)
Associate Chief
Section of Critical Care Assistant Professor
Department of Medicine Division of Pulmonary
Critical Care & Sleep Medicine Section of Critical Care Medicine
National Jewish Health
Denver, CO

Dr. Solomon discloses that he is a speaker for Genentech.

Zulma Yunt, MD
Assistant Professor
Department of Medicine Division of Pulmonary
Critical Care & Sleep Medicine Section of Critical Care Medicine
National Jewish Health
Denver, CO

Dr. Yunt discloses that she is a speaker for Boehringer Ingelheim.

Jonathan Chung, MD
Associate Professor of Radiology Section Chief
Thoracic Radiology Interim Chief of Quality
Department of Radiology University of Chicago Medical Center
Chicago, IL

Dr. Chung discloses that he is a speaker for Boehringer Ingelheim and Genentech.

Planners and Managers

Stephanie Corder, ND, RN, CHCP, has no financial relationships to disclose.
Andrea Harshman, MHA, CHCP, CMP-HC, has no financial relationships to disclose.
Harold Nelson, MD, discloses that he is a Consultant and Speaker for ALK and on a Data Safety Monitoring Board for Pearl therapeutics.

Credit

1.00

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

National Jewish Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement

National Jewish Health designates this live educational activity for a maximum of 1.00 AMA PRA Category 1 CreditTM  .  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Instructions

To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

If you have any questions relating to the accreditation of this activity, please contact National Jewish Health at: proed@nationaljewish.org or call (303) 398-1000.

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue